Skip to main navigation Utility PATIENTS CAREERS CONTACT US Press Releases YEAR 2021 NOV 15 Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results NOV 9 Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis OCT 27 Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program OCT 21 Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint SEP 22 Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points SEP 8 Frequency Therapeutics to Present at Upcoming Investor Conferences AUG 12 Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results MAY 25 Frequency Therapeutics to Present at Upcoming Jefferies and Goldman Sachs Healthcare Investor Conferences MAY 20 Frequency Therapeutics Provides Statement of Support for the Hearing Loss Association of America’s Externally-Led Patient-Focused Drug Development Meeting to Address Sensorineural Hearing Loss MAY 13 Frequency Therapeutics Provides Business Updates and Reports First Quarter 2021 Financial Results Pagination CURRENT PAGE 1 PAGE 2 NEXT PAGE NEXT › LAST PAGE LAST » Displaying 1 - 10 of 18 Interested in joining our team? Explore careers © 2021 Frequency Therapeutics Open Positions Contact Privacy Policy Terms and conditions

Our Program for Multiple Sclerosis Frequency is following early restorative signals in multiple sclerosis to develop medicines with the same underlying regenerative science we are bringing to hearing loss. Multiple sclerosis (MS) is a neurological disease that affects nearly 1 million people in the United States. The disabling condition is caused by an immune attack on myelin, the insulating material that coats and protects axons in the brain. Like an electrical wire that’s been stripped of its protective covering, nerves with damaged myelin cannot send signals through the brain. As myelin breaks down, patients with MS experience a variety of symptoms ranging from sensory and motor deficits (particularly sight and touch) to muscle weakness and walking difficulties, cognitive challenges and fatigue. Interested in joining our team? Explore careers © 2021 Frequency Therapeutics Open Positions Contact Privacy Policy Terms & Conditions